{"title":"Mechanism of inhibition of growth and metastasis of colon cancer by celecoxib analog OSU-03013 via wnt signaling pathway","authors":"ChunYong Yang, ZhiQiang Zhou, XueSong Wang, JianZhe Ren, Jing Qi","doi":"10.32383/appdr/175914","DOIUrl":null,"url":null,"abstract":"OSU-03013 is a structurally modified analog of celecoxib. This study probed the antitumor activity of OSU-03013 on colon cancer (CC) and explored its possible mechanism. CCK-8 method was used to evaluate the activity of OSU-03013 on CC cell SW480 and normal colon epithelial cell FHC, and the anti-proliferation effect of OSU-03013 was detected by CCK-8 and colony formation assay. In addition, flow cytometry and Annexin V-FITC/PI were applied to detect apoptosis of SW480 cells, and Transwell was to detect cell migration and invasion. β-catenin, c-myc, and Wnt1 genes were assessed by RT-qPCR, and E-cadherin, N-cadherin, and β-catenin, c-myc, mTOR, p-mTOR, and Wnt1 proteins were detected by Western Blot. OSU-03013 had dose-dependent and time-dependent antitumor activity on SW480 cells, which can promote tumor cell apoptosis, up-regulate E-cadherin, and down-regulate β-catenin, c-myc, Wnt1, and N-cadherin. OSU-03013 has anti-tumor activity on CC cells. The anti-cancer mechanism of OSU-03013 is achieved by inhibiting the activation of Wnt pathway genes and inhibiting tumor invasion and metastasis. This study provides a scientific basis for the clinical application of OSU-03013 in the treatment of CC.","PeriodicalId":7135,"journal":{"name":"Acta Poloniae Pharmaceutica - Drug Research","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Poloniae Pharmaceutica - Drug Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.32383/appdr/175914","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
OSU-03013 is a structurally modified analog of celecoxib. This study probed the antitumor activity of OSU-03013 on colon cancer (CC) and explored its possible mechanism. CCK-8 method was used to evaluate the activity of OSU-03013 on CC cell SW480 and normal colon epithelial cell FHC, and the anti-proliferation effect of OSU-03013 was detected by CCK-8 and colony formation assay. In addition, flow cytometry and Annexin V-FITC/PI were applied to detect apoptosis of SW480 cells, and Transwell was to detect cell migration and invasion. β-catenin, c-myc, and Wnt1 genes were assessed by RT-qPCR, and E-cadherin, N-cadherin, and β-catenin, c-myc, mTOR, p-mTOR, and Wnt1 proteins were detected by Western Blot. OSU-03013 had dose-dependent and time-dependent antitumor activity on SW480 cells, which can promote tumor cell apoptosis, up-regulate E-cadherin, and down-regulate β-catenin, c-myc, Wnt1, and N-cadherin. OSU-03013 has anti-tumor activity on CC cells. The anti-cancer mechanism of OSU-03013 is achieved by inhibiting the activation of Wnt pathway genes and inhibiting tumor invasion and metastasis. This study provides a scientific basis for the clinical application of OSU-03013 in the treatment of CC.